Optimum’s clients build momentum in March

Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million.

On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101.

The company will also present preclinical data on other drug candidates from its proprietary ADC technology platform at the American Association for Cancer Research (AACR) Annual Meeting, being held in San Diego, California on the 5 – 10 April 2024.


Bayer holds Capital Markets Day

On Tuesday 5 March, our client Bayer AG held its 2024 Capital Markets Day, updating the market on the business and the management’s plans for turning around the company.


Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin

Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, on Tuesday announced the opening of its new laboratory facilities on Thursday at its Berlin headquarters.


AMSilk and BRAIN Biotech’s protein engineering collab successfully improves structural proteins for performance materials

BRAIN Biotech AG, leading provider of solutions for the biotech industry, and AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, on Tuesday announced the successful completion of the first phase of a development collaboration.


Fibrocor Therapeutics begins R&D collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

Fibrocor Therapeutics Inc., a privately held developer of novel therapeutics to treat fibrosis, today announces that it has entered into a research and development collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD) to advance its Alport Syndrome program.


Novo Holdings Venture Investments highlights 2023 successes

The Novo Holdings Venture Investments team on Tuesday published a review of its investments for last year in its 2023 Newsletter, highlighting a record year advancing innovative therapies for patients. Highlights included 18 new portfolio investments, five portfolio companies acquired, $766 million invested and committed and $600 million of cash exit proceeds.


Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, on Wednesday announced the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).


Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

The Novo Nordish Foundation on Wednesday highlighted its support for science, education, innovation and development initiatives in 2023. In 2023, the Foundation awarded more than DKK 9.1 billion (more than $1.3 billion) in philanthropic grants and investments and supported a total of 751 new projects.


Women in Life Science Denmark (WiLD) hosts network meeting in collaboration with DANISH BIO to promote equity in the Danish life science industry

Women in Life Science Denmark (WiLD) hosted a networking event in partnership with DANISH BIO in Copenhagen on Thursday.


Calliditas announces FDA granted orphan drug exclusivity of seven years for Tarpeyo

Calliditas Therapeutics AB on Thursday announced that the FDA has granted an orphan drug exclusivity period of seven years for Tarpeyo (budesonide) expiring in December 2030 based on when the Company obtained full approval with a new indication for this drug product.


BioInnovation Institute provides financial support as six promising companies enter the Venture House program

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, on Thursday announced that six companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth.


US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy

iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer therapies, on Thursday announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer.


Congratulations to Allan Marchington and ICG on £100 million investment from British Business Bank

The Optimum team would like to extend its congratulations to ICG, the global alternative asset manager, which on Wednesday announced it has been selected by the British Business Bank to receive £100m  investment from the new Long-term Investment for Technology and Science (LIFTS) initiative. Allan Marchington, head of life sciences for ICG, is a friend of Optimum and supporter of our Annual Healthcare Investor Conference, which is taking place in October.


Lytix Biopharma the star of Optimum Podcast #17

Following recent encouraging interim clinical results, Øystein Rekdal, CEO of Lytix Biopharma, is featured in the latest edition of the Optimum Perspectives Podcast.

Rekdal discusses with Optimum’s Nick Bastin how the company’s lead candidate LTX-315 has a unique approach to killing cancer. The podcast is available on all major channels, check it out today!